|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
intravenous
|
|
gptkbp:approvalYear
|
2008
|
|
gptkbp:approvedBy
|
gptkb:Germany
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
N03AX18
|
|
gptkbp:CASNumber
|
175481-36-4
|
|
gptkbp:chemicalFormula
|
C13H18N2O3
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_V_(US)
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:eliminationHalfLife
|
13 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
intravenous solution
oral solution
|
|
gptkbp:genericName
|
gptkb:lacosamide
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vimpat
|
|
gptkbp:indication
|
adjunctive therapy for partial-onset seizures
monotherapy for partial-onset seizures
treatment of primary generalized tonic-clonic seizures (in some regions)
|
|
gptkbp:KEGGID
|
D08102
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:UCB
|
|
gptkbp:mechanismOfAction
|
enhances slow inactivation of voltage-gated sodium channels
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:patent
|
gptkb:UCB
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
less than 15%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL573
99477
DB06218
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
dizziness
fatigue
headache
ataxia
diplopia
|
|
gptkbp:synonym
|
gptkb:lacosamide
|
|
gptkbp:UNII
|
O4L1XPO44W
|
|
gptkbp:usedFor
|
epilepsy
partial-onset seizures
|
|
gptkbp:bfsParent
|
gptkb:UCB_Biopharma
gptkb:UCB_Pharma
|
|
gptkbp:bfsLayer
|
7
|